Abstract
The UK Medical Research Council conducted this trial of carboplatin chemotherapy in advanced seminoma to compare single agent carboplatin with a standard combination of etoposide with cisplatin. The use of single agent carboplatin was expected to be associated with reduced toxicity. A total of 130 patients with advanced seminoma were randomly assigned to treatment with either single agent carboplatin (C) at a dose of 400 mg/m2 to be corrected for glomerular filtration rate outside the range 81–120 ml min–1 and to be administered on day 1 of a 21 day cycle to a total of 4 cycles or to etoposide + platinum (EP). The trial was designed as an equivalence study aiming to exclude a reduction in the 3-year progression-free survival in patients allocated to carboplatin of between 10 and 15%, requiring initially a target accrual of 250 patients (90% power significance level 5% (one-sided)). The trial closed after 130 patients had been randomized following recommendation by an independent data monitoring committee. At a median follow-up time of 4.5 years, 81% of patients had been followed up for at least 3 years and 19 patients have died. The estimated PFS rate (95% Confidence Intervals (CI)) at 3 years was 71% (60–82%) in patients allocated C and 81% (71–90%) in those allocated EP; the 95% CI for the difference in 3 year PFS was –6% to +19%. The hazard ratio of 0.64 (95% CI 0.32–1.28) favoured EP but the difference was not statistically significant (log rank chi-squared = 1.59 P = 0.21). The 3-year survival rate was 84% (75–92%) in those allocated C, and 89% (81–96%) in those allocated EP. The hazard ratio for survival was 0.85 with 95% CI, 0.35–2.10, log rank chi-squared = 0.12, P = 0.73. The trial has not demonstrated statistically significant differences in the major survival endpoints comparing single agent carboplatin with a combination of etoposide + cisplatin. This cannot be taken as an indication of equivalence since the limited size of this trial rendered it unable to exclude a 19% lower progression-free survival and survival in those treated with single agent carboplatin which would be important clinically. Standard initial chemotherapy for advanced seminoma should be based on cisplatin combinations and the role of carboplatin awaits the outcome of further studies. © 2000 Cancer Research Campaign http://www.bjcancer.com
Article PDF
Similar content being viewed by others
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bajorin DF, Sarosdy MF and Pfister DG (1993) Randomised trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumours: A Multi-institutional Study. J Clin Oncol 11: 598–606
Clemm C, Bokemeyer C and Gerl A (2000) Randomized trial comparing cisplatin/etoposide/ ifosfamide with carboplatin monochemotherapy in patients with advanced metastatic seminoma. Proc ASCO 19: 326a
Dieckmann K-P, Bornhoeft G and Huland H (1990) Ambulante carboplatin-monotherapie beim fortgeschrittenen seminom. Urologe A 29: 281–285
Duchesne GM, Stenning SP and Aass N (1997) Radiotherapy after chemotherapy for metastatic seminoma – a diminishing role. MRC Testicular Tumour Working Party. Eur J Cancer 33: 829–835
Einhorn LH and Williams SD (1980) Chemotherapy of disseminated seminoma. Cancer Clin Trials 3: 307–313
Einhorn LH, Williams SD and Loehrer PJ (1989) Evaluation of optimal duration of chemotherapy in favourable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol 7: 387–391
Fosså SD and Horwich A (1997) Current status of chemotherapy in advanced seminoma [editorial]. Eur J Cancer 33: 181–183
Fosså SD, Oliver RT and Stenning SP (1997) Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy. Eur J Cancer 33: 1380–1387
Horwich A and Dearnaley DP (1992) Treatment of seminoma. Semin Oncol 19: 171–180
Horwich A, Dearnaley DP and Duchesne GM (1989) Simple nontoxic treatment of advanced metastatic seminoma with carboplatin. J Clin Oncol 7: 1150–1156
Horwich A, Sleijfer DT and Fossa SD (1997) Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 15: 1844–1852
Loehrer PJ, Johnson D and Elson P (1995) Importance of bleomycin in favourable-prognosis disseminated germ cell tumors: An Eastern Cooperative Oncology Group Trial. J Clin Oncol 13: 470–476
Logothetis CJ, Samuels ML and Ogden SL (1987) Cyclophosphamide and sequential Cisplatin for advanced seminoma: long-term follow-up in 52 patients. J Urol 138: 789–794
Mencel PJ, Motzer RJ and Mazumdar M (1994) Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients. J Clin Oncol 12: 120–126
Motzer RJ, Bosl GJ and Geller NL (1988) Advanced seminoma: the role of chemotherapy and adjunctive surgery. Ann Intern Med 108: 513–518
Oliver RTD (1988) Long-term follow-up of single agent cisplatin in metastatic seminoma and surveillance for Stage I seminoma. Presented at the 24th Annual Meeting, ASCO. Proc Am So Clin Oncol 7: 120
Oliver RTD, Edmonds PM and Ong JYH (1994) Pilot studies of 2 and 1 course carboplatin as adjuvant for stage I seminoma: should it be tested in a randomized trial against radiotherapy?. Int J Radiat Oncol Biol Phys 29: 3–8
Peckham MJ, McElwain TJ and Barrett A (1979) Combined management of the malignant teratoma of the testis. The Lancet 1: 267–270
Puc HS, Heelan R and Mazumdar M (1996) Management of residual mass in advanced seminoma: Results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol 14: 454–460
Samuels ML, Lanzotti VJ and Holoye PY (1976) Combination chemotherapy in germinal cell tumor. Cancer Treat Rev 3: 185–204
Samuels ML and Logothetis CJ (1983) Follow-up study of sequential weekly pulse Cis-platinum for advanced seminoma. Proc Am Soc Clin Oncol 2: 137
Schmoll H-J, Bokemeyer C and Harstrick A (1991) Single agent carboplatinum (CBDCA) for advanced seminoma: A phase II study. Proc Am Soc Clin Oncol 10: 181
Schultz SM, Einhorn LH and Conces DJJ (1989) Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University Experience. J Clin Oncol 7: 1497s–1503
Author information
Authors and Affiliations
Consortia
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Horwich, A., Oliver, R., Wilkinson, P. et al. A Medical Research Council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. Br J Cancer 83, 1623–1629 (2000). https://doi.org/10.1054/bjoc.2000.1498
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1498
- Springer Nature Limited
Keywords
This article is cited by
-
A case of cisplatin-refractory advanced pure seminoma showing complete remission after treatment with high-dose carboplatin plus etoposide as fourth-line salvage chemotherapy
International Cancer Conference Journal (2018)
-
Regression of metastatic seminoma in a patient referred for carcinoma of unknown primary origin
Nature Reviews Urology (2010)
-
Why does cytotoxic chemotherapy cure only some cancers?
Nature Clinical Practice Oncology (2009)
-
Good-risk-advanced germ cell tumors: historical perspective and current standards of care
World Journal of Urology (2009)